Csaba Juhász and Harry T. Chugani
- Published in print:
- 2010
- Published Online:
- January 2011
- ISBN:
- 9780195342765
- eISBN:
- 9780199863617
- Item type:
- chapter
- Publisher:
- Oxford University Press
- DOI:
- 10.1093/acprof:oso/9780195342765.003.0009
- Subject:
- Neuroscience, Disorders of the Nervous System
The interictal FDG PET often shows focal cortical hypometabolism in patients with extratemporal epilepsy and can correctly regionalize neocortical epileptic foci in more than 2/3 of the cases, even ...
More
The interictal FDG PET often shows focal cortical hypometabolism in patients with extratemporal epilepsy and can correctly regionalize neocortical epileptic foci in more than 2/3 of the cases, even if MRI is non-localizing. In some cases, however, FDG PET overestimates the epileptogenic region, and hypometabolism may extend progressively to involve remote cortical and subcortical regions, thus establishing an epileptic network in chronic epilepsy. On the other hand, hypometabolism can occur adjacent to, rather than completely overlap with, ictal seizure onset zones. Therefore, FDG PET is best used for presurgical evaluation in combination with other clinical, electrophysiological and imaging data to guide intracranial grid placement and optimize tailored neocortical resection. When applied in this manner, the use of FDG PET can improve outcome of extratemporal lobe epilepsy surgery.Less
The interictal FDG PET often shows focal cortical hypometabolism in patients with extratemporal epilepsy and can correctly regionalize neocortical epileptic foci in more than 2/3 of the cases, even if MRI is non-localizing. In some cases, however, FDG PET overestimates the epileptogenic region, and hypometabolism may extend progressively to involve remote cortical and subcortical regions, thus establishing an epileptic network in chronic epilepsy. On the other hand, hypometabolism can occur adjacent to, rather than completely overlap with, ictal seizure onset zones. Therefore, FDG PET is best used for presurgical evaluation in combination with other clinical, electrophysiological and imaging data to guide intracranial grid placement and optimize tailored neocortical resection. When applied in this manner, the use of FDG PET can improve outcome of extratemporal lobe epilepsy surgery.
Rachel Mistur, Lisa Mosconi, Remigiusz Switalski, Susan De Santi, Yi Li, Lidia Glodzik, Miroslaw Brys, Wai Tsui, Henry Rusinek, and Mony J. de Leon
- Published in print:
- 2009
- Published Online:
- February 2010
- ISBN:
- 9780195328875
- eISBN:
- 9780199864836
- Item type:
- chapter
- Publisher:
- Oxford University Press
- DOI:
- 10.1093/acprof:oso/9780195328875.003.0011
- Subject:
- Neuroscience, Techniques, Development
Reductions in the cerebral metabolic rate of glucose (CMRglc), a measure of neuronal function, have proven to be a promising tool in the early diagnosis of Alzheimer's disease (AD). FDG-PET imaging ...
More
Reductions in the cerebral metabolic rate of glucose (CMRglc), a measure of neuronal function, have proven to be a promising tool in the early diagnosis of Alzheimer's disease (AD). FDG-PET imaging demonstrates progressive CMRglc reductions in AD patients, the extent and topography of which correlate with symptom severity. There is increasing evidence that hypometabolism appears during the preclinical stages of AD and can predict decline years before the onset of symptoms. This chapter provides an overview of FDG-PET results in individuals at risk for developing dementia, including presymptomatic individuals carrying mutations responsible for early-onset familial AD, patients with mild cognitive impairment (MCI), nondemented carriers of the Apolipoprotein E (ApoE) e4 allele, cognitively normal subjects with a family history of AD, subjects with subjective memory complaints, and the normal elderly followed longitudinally until they expressed the clinical symptoms of AD. Finally, this chapter discusses the potential to combine different PET tracers and cerebrospinal fluid (CSF) markers of pathology to improve the early detection of AD.Less
Reductions in the cerebral metabolic rate of glucose (CMRglc), a measure of neuronal function, have proven to be a promising tool in the early diagnosis of Alzheimer's disease (AD). FDG-PET imaging demonstrates progressive CMRglc reductions in AD patients, the extent and topography of which correlate with symptom severity. There is increasing evidence that hypometabolism appears during the preclinical stages of AD and can predict decline years before the onset of symptoms. This chapter provides an overview of FDG-PET results in individuals at risk for developing dementia, including presymptomatic individuals carrying mutations responsible for early-onset familial AD, patients with mild cognitive impairment (MCI), nondemented carriers of the Apolipoprotein E (ApoE) e4 allele, cognitively normal subjects with a family history of AD, subjects with subjective memory complaints, and the normal elderly followed longitudinally until they expressed the clinical symptoms of AD. Finally, this chapter discusses the potential to combine different PET tracers and cerebrospinal fluid (CSF) markers of pathology to improve the early detection of AD.
